Oncology & Cancer

Treatments compared for advanced renal cell carcinoma

(HealthDay)—For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus ipilimumab versus sunitinib have longer treatment-free survival (TFS), according to a study published online ...

Oncology & Cancer

CheckMate 743 shows that dual immunotherapy, nivolumab + ipilimumab

The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research ...

page 1 from 5

Ipilimumab

Ipilimumab (also known as MDX-010 or MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved human monoclonal antibody developed by Bristol-Myers Squibb, and works by activating the immune system.

Additionally, ipilimumab is undergoing clinical trials for the treatment of non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC) and metastatic hormone-refractory prostate cancer.

This text uses material from Wikipedia, licensed under CC BY-SA